Under the terms of the agreement, Strides will collaborate with Kenox on the development and regulatory filing of multiple nasal spray products for the US market, spanning various therapeutic indications.

The partnership aims to leverage Kenox’s specialized expertise in OINDPs and Strides’ strong presence in regulated markets.

“We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space,” said Aditya Kumar, executive director – business development, Strides Pharma Science. “Nasal sprays have consistently been a key focus area for Strides, and this collaboration builds on the solid progress we’ve already made in this domain. With our continued investments in capabilities and capacities at our US facility, these products are a natural extension of our strategy to grow in the nasal spray technology segment. Kenox’s formulation and development strengths perfectly complement our manufacturing and go-to-market capabilities, enabling us to accelerate the expansion of our nasal spray portfolio in the US market.”

Dr. Sitaram Velaga, founder, president, and CEO of Kenox Pharmaceuticals Inc., added, “Our strategic partnership with Strides marks a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and enables us to leverage our capabilities to bring important drug products to patients worldwide at an affordable price.”

The partnership aims to advance a pipeline of nasal spray products for the US market, combining Strides’ strong commercial presence with Kenox’s specialized OINDP expertise to deliver high-quality, affordable therapies to patients.

The company’s consolidated net profit plunged 96.8% to Rs 105.59 crore in Q1 FY26, compared to Rs 3,349.58 crore reported in Q1 FY25. Meanwhile, net sales increased 6.2% year-on-year to Rs 1,119.47 crore during the quarter.

Shares of Strides Pharma Science rose 0.07% to Rs 881.70 on the BSE.